BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $88 from $90 but keeps an Outperform rating on the shares. The company expects to disclose pivotal data evaluating vepdegestrant in ER+/HER2- breast cancer patients in Q1 of 2025, and the firm is maintaining its positive view on Arvinas’ protein degrader platform and ARV-471 in ER+/HER2- breast cancer, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio